Beta Drugs

Name

Beta Drugs

Legal name

Beta Drugs Limited

Website

https://betadrugslimited.com

Company type

Public

Founded year

1985

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industries

Small-Molecule API Commercial Manufacturing (HLAGAHAB), Small-Molecule API Process Development & Route Scouting (HLAGAHAA), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

Keywords

• Oncology drug manufacturing
• Anti-cancer formulations
• Pharmaceutical contract manufacturing
• Active pharmaceutical ingredients
• Novel drug delivery systems

Headquarters

HQ city

Haryana

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Oncology Formulation Sales: Sale of proprietary and in-house manufactured anti-cancer medications including tablets, capsules, liquid injections, and lyophilized injections across domestic and international markets. 80 products are own-manufactured with in-house API.
2. Contract Manufacturing: Contract manufacturing services for prominent pharmaceutical companies in India. Beta Drugs is recognized as a premier contract manufacturing company by numerous Indian pharma firms for superior quality standards.
3. API Development & Sales: Active Pharmaceutical Ingredient development and manufacturing through Adley Lab India facility in Derabassi, Punjab. The company produces oncology APIs with two production lines (60 and 30 tonnes p.a.) and supplies both internally and externally.
4. Nivian Lifesciences Acquisition (Women's Health): Acquisition of 66.09% controlling stake in Nivian Lifesciences for Rs 69.4 crore, expanding into women's health and fertility drug segment. Nivian projects FY26 sales of ~Rs 43 crore.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels3 records

Core offering

Beta Drugs Limited manufactures and commercializes oncology pharmaceutical formulations including tablets, capsules, liquid injections, lyophilized injections, and Novel Drug Delivery System (NDDS) products such as Nanoparticle-Albumin-Bound Paclitaxel, Ready-to-Use Docetaxel, and Gemcitabine. The company also provides Active Pharmaceutical Ingredient (API) development and contract manufacturing services through WHO-GMP certified plants, with its in-house oncology API facility (Adley Lab India) producing oncological APIs across two production lines with combined 90 tonnes annual capacity.

Product overview

Beta Drugs Limited is an oncology-focused pharmaceutical company operating as a division of the Adley Group. The company manufactures a diverse portfolio of anti-cancer medications (Oncology Products) and dermatological solutions (Cosmeceutical Products), supported by in-house API development and contract manufacturing services. The product portfolio includes NDDS (Novel Drug Delivery System) formulations such as Nanoparticle-Albumin-Bound Paclitaxel, Ready-to-Use Docetaxel, and Gemcitabine, as well as oral solutions like Methotrexate Oral Solution and Caxfila-OS. The company operates three manufacturing facilities: Beta Drugs Ltd India (formulation plant), Adley Formulations India (WHO-GMP approved formulation plant), and Adley Lab India (API plant), with operations spanning over 46 countries globally.

Differentiator

Problem solved

Functional benefit

Products and services

• Oncology Products Comprehensive portfolio of anti-cancer medications including chemotherapy drugs and NDDS formulations (tablets, capsules, liquid injections, lyophilized injections, oral suspensions) for hospitals, oncologists, and cancer patients across India and 46 international markets.
• Cosmeceutical Products Dermatological solutions and skin health products at the intersection of cosmetics and pharmaceuticals, addressing ever-growing concerns surrounding skin health in the Indian market.
• Contract Manufacturing Services WHO-GMP approved contract manufacturing services for prominent pharmaceutical companies in India, producing tablets, capsules, liquid and lyophilized injections, and prefilled syringes for oncology and other formulations.
• API Development and Manufacturing Active Pharmaceutical Ingredient development and manufacturing focused on novel synthesis routes, process refinements, and cost advantages, including oncological APIs produced at the WHO-GMP certified Adley Lab India facility in Derabassi, Punjab with combined annual capacity of 90 tonnes.
• Nanoparticle-Albumin-Bound Paclitaxel NDDS formulation of paclitaxel using nanoparticle albumin-bound technology for enhanced cancer drug delivery, successfully developed and commercialized by Beta Drugs as a leader in NDDS among Indian oncology companies.
• Ready-to-Use Docetaxel Novel drug delivery system formulation of docetaxel developed and commercialized by Beta Drugs, offered as a ready-to-use oncology formulation for cancer treatment.
• Gemcitabine (NDDS formulation) Chemotherapy medication developed and commercialized as an NDDS formulation by Beta Drugs for oncology treatment, intended for hospital and clinical use in cancer care.
• Caxfila-OS (Megestrol Acetate Suspension 40mg/ml) First NDDS formulation of Megestrol Acetate Suspension 40mg/ml in India, for managing anorexia, cachexia, and significant weight loss in cancer and AIDS patients.
• Methotrexate Oral Solution First Indian company to receive DCGI approval for Methotrexate Oral Solution, a patient-friendly, bioequivalent alternative to tablet form for acute lymphoblastic leukemia, lymphomas, solid tumors, rheumatoid arthritis, juvenile idiopathic arthritis, and psoriasis.

Quantifiable outcome

• 150+ SKUs across Oncology & Dermatology with 30% CAGR growth
• +3 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Nivian Lifesciences Private LimitedcoreStrategic or Co-development Partner · 12 January 2026Beta Drugs entered into a definitive agreement to acquire a 66.09% controlling stake in Nivian Lifesciences Private Limited for Rs 69.4 crore, valuing the IVF-focused company at approximately Rs 105 crore. This acquisition marks Beta Drugs' strategic entry into the women's health and fertility drug segment. Nivian, established in 2019, projects FY26 sales of approximately Rs 43 crore with net sales of Rs 30.3 crore for the nine months ending December 2025.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Sun Pharmaceutical Industries: India's largest pharmaceutical company with oncology, dermatology, and specialty formulations globally. A broad incumbent in overlapping therapeutic areas, providing context for what scaled Indian oncology-pharma leadership looks like.
• Zydus Lifesciences: Indian pharmaceutical company with oncology, dermatology, and women's health portfolios, plus API manufacturing. Comparable to Beta Drugs across multiple overlapping segments (oncology formulations, dermatology/cosmeceuticals, API), though at meaningfully larger scale.
• Dr. Reddy's Laboratories: Major Indian pharmaceutical company with oncology, API, and contract manufacturing operations. Comparable as an India-based pharma with backward-integrated API and global regulatory footprint, though at significantly larger scale than Beta Drugs.
• Cipla: One of India's largest pharmaceutical companies with a broad oncology and specialty portfolio, including NDDS formulations. A larger incumbent competing in the same oncology manufacturing space with deeper R&D and global commercial reach than Beta Drugs.
• Aurobindo Pharma: Large Indian pharmaceutical manufacturer with API, formulations, and oncology exposure across global markets. Comparable to Beta Drugs as an Indian pharma with backward-integrated API manufacturing and broad international registrations.

Direct peers

• Emcure Pharmaceuticals: Indian pharma with significant presence in oncology, women's health (including fertility/IVF), and contract manufacturing. Especially relevant given Beta Drugs' recent entry into women's health via the Nivian Lifesciences acquisition, overlapping with Emcure's existing franchise.
• Shilpa Medicare: Indian pharma focused on oncology APIs and formulations, with NDDS capabilities including liposomal and nanoparticle formulations. Closely comparable to Beta Drugs in therapeutic focus, formulation technology, and customer segments in semi-regulated markets.
• Bharat Serums and Vaccines (BSV): Indian specialty biopharmaceutical company focused on complex generics, oncology, and women's health (including fertility products). Comparable to Beta Drugs in oncology and women's health product overlap, as well as contract manufacturing for complex injectables.
• Natco Pharma: Indian pharmaceutical company with a strong focus on oncology, including complex generics and novel drug delivery formulations. Directly comparable to Beta Drugs given overlapping oncology manufacturing capabilities, API backward integration, and global distribution in semi-regulated markets.

Regional players

• Strides Pharma: Indian pharmaceutical company focused on regulated and emerging markets with oncology and complex generics exposure. Comparable in international distribution strategy (regulated + semi-regulated markets) and contract manufacturing capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/betadrugsltd

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Beta Drugs